Bellevue Life Sciences Acquisition Corp. 8-K Filing

TL;DR

BLAC discloses its capital structure: common stock, $11.50 warrants, and fractional share rights.

AI Summary

Bellevue Life Sciences Acquisition Corp. filed an 8-K on August 16, 2024, reporting an event on August 13, 2024. The filing details the company's structure, including common stock, redeemable warrants exercisable at $11.50, and rights to receive fractional shares. The company is incorporated in Delaware and its fiscal year ends on December 31.

Why It Matters

This filing provides essential details about the capital structure of Bellevue Life Sciences Acquisition Corp., including its common stock, warrants, and rights, which are crucial for investors to understand their potential holdings and rights.

Risk Assessment

Risk Level: low — This is a routine 8-K filing detailing the company's capital structure and does not indicate any immediate financial distress or significant operational changes.

Key Numbers

• $11.50 — Warrant Exercise Price (Price at which redeemable warrants can be exercised for common stock.)

Key Players & Entities

• Bellevue Life Sciences Acquisition Corp. (company) — Registrant
• August 13, 2024 (date) — Earliest event reported
• August 16, 2024 (date) — Filing date
• $11.50 (dollar_amount) — Redeemable warrant exercise price
• Delaware (jurisdiction) — State of incorporation

FAQ

Key Financial Figures

• $0.0001 — ck Market LLC Common stock, par value $0.0001 per share BLAC The Nasdaq Stock Mar
• $11.50 — of common stock at an exercise price of $11.50 per share BLACW The Nasdaq Stock Ma
• $50,000 — 01. Other Events. On August 13, 2024, $50,000 was deposited in the trust account in c

Filing Documents

• d866823d8k.htm (8-K) — 27KB
• 0001193125-24-202145.txt ( ) — 204KB
• blacu-20240813.xsd (EX-101.SCH) — 5KB
• blacu-20240813_def.xml (EX-101.DEF) — 15KB
• blacu-20240813_lab.xml (EX-101.LAB) — 26KB
• blacu-20240813_pre.xml (EX-101.PRE) — 16KB
• d866823d8k_htm.xml (XML) — 9KB

From the Filing

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 BELLEVUE LIFE SCIENCES ACQUISITION CORP. (Exact Name of Registrant as Specified in Charter) Delaware 001-41390 84-5052822 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 10900 NE 4th Street , Suite 2300 , Bellevue , WA 98004 (Address of Principal Executive Offices) (Zip Code) Registrant's telephone number, including area code (425) 635-7700 Not Applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e 4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Units, each consisting of one share of common stock, one redeemable warrant and one right BLACU The Nasdaq Stock Market LLC Common stock, par value $0.0001 per share BLAC The Nasdaq Stock Market LLC Redeemable warrants, exercisable for shares of common stock at an exercise price of $11.50 per share BLACW The Nasdaq Stock Market LLC Right to receive one-tenth (1/10) of one share of common stock BLACR The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item8.01. Other Events. On August 13, 2024, $50,000 was deposited in the trust account in connection with the extension of the date by which the Company must consummate a business combination. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: August 16, 2024 BELLEVUE LIFE SCIENCES ACQUISITION CORP. By: /s/ Kuk Hyoun Hwang Name: Kuk Hyoun Hwang Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR